Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-25
1997-05-20
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 39, 546 37, A61K 31445, C07D22102
Patent
active
056312636
ABSTRACT:
A therapeutic method is provided to elevate a depressed mammalian autologous mixed lymphocyte response and to alleviate the diseases associated therewith by the administration of an effective amount of certain selective delta opioid receptor antagonists to a mammal such as a human patient in need of such treatment.
REFERENCES:
patent: 4816586 (1989-03-01), Portoghese et al.
patent: 5244904 (1993-09-01), Nagase et al.
patent: 5332818 (1994-07-01), Nagase et al.
E. E. Abdelhamid et al., "Selective Blockade of Delta Opioid Receptors Prevents the Developement of Morphine Tolerance and Dependence in Mice," J. Pharmacol. Exp. Therap., 258, 299-303 (1991).
T. Akami et al., "Cytoprotective Effect of CD59 Antigen on Xenotransplantation Immunity," Transplantation Proc., 24, 485-487 (Apr. 1992).
K. Arakawa et al., "The Immunosuppressive Effect of .delta.-Opioid Receptor Antagonist on Rat Renal Allograft Survival," Transplantation, 53, 951-953 (Apr. 1992).
K. Arakawa et al., "Immunosuppressive Effect of .delta.-Opioid Receptor Antagonist on Xenogenic Mixed Lymphocyte Reaction," Transplantation Proc., 24 696-697 (Apr. 1992).
K. Arakawa et al., "Delta Receptor Antagonist for Immunosupression after Rat Kidney Transplantation," College of Problems of Drug Dependence and International Narcotics Research Conference, p. 102, Abstract No. 018, (Jun. 24, 1992).
R. Cotton et al., "ICI 174846: A Highly Selective Antagonist for the Opioid .delta.-Receptor," Eur. J. Pharmacol., 97, 331-332 (1984).
W. E. Crowe et al., "The Autologous Mixed Lymphocyte Reaction is Decreased in Freund's Adjuvant-Injected Rats of Arthritis-Suseptible Strains," Arthritis Rheumatism, 28, 537-541 (May 1985).
E. C. Ebert et al., "Diminished Interleukin 2 Production and Receptor Generation Characterize the Aquired Immunodificiency Syndrome," Clin. Immunol. Immunopathol.37, 283-297 (1985).
R. E. Faith et al., "Enhancement of Host Resistance to Viral and Tumor Challenge by Treatment with Methionine-Enkaphalin," Annals New York Acad. Sci., 496. 137-145 (1987).
R. E. Fatih et al., "Mechanisms of Tolerance and Dependence," NIDA Res. Monograph, 54, 300-311 (1984).
J. C. Froelich et al., "Delta Opioid Amtagonists Produce Prolonged Supression of Ethanol Intake", Alcoholism: Clin. Exp. Res., p. 315, Abstract No. 20 (1991).
S. Gupta et al., "Autologous Mixed Lymphocyte Reaction in Health and Disease States in Man," Vox Sang., 44, 265-288 (1983).
J. K. Gutowski et al., "Studies on the Syngeneic Mixed Lymphocyte Reaction II. Decline in the Syngeneic Mixed Lymphocyte Reaction with Age," Immunol., 46, 801-808 (1982).
D. A. Hafler et al., "Interleukin-1 Corrects the Defective Autologous Mixed Lymphocyte Response in Multiple Sclerosis," Clin. Immunol. Immunopathol., 58, 115-125 (1991).
D. A. Hafler et al., "MS: A CNS and Systemic Autoimmune Disease," Immunol. Today, 10, 104-107 (1989).
T. Han et al., "Lack of Autologous Mixed Lymphocyte Reaction in Patients with Chronic Lymphocyte Leukemia: Evidence for Autoreactive T-Cell Dysfunction not Correlated with Phenotype, Karyotype, or Clinical Studies," Blood, 60, 1075-1081 (1982).
R. L. Hirsch et al., "Defective Autologous Mixed Lymphocyte Reactivity in Multiple Sclerosis," Clin. Exp. Immunol., 64, 107-113 (1986).
M. Hendrickson et al., "Naloxone Inhibits the In Vivo Immunosuppressive Effects of Morphine and Thermal Injury in Mice," J. Burn Care Rehab., 10, 494-498 (Nov./Dec. 1989).
B. D. Jankovic et al., "Enkephalins Modulate in Vivo Immune Reactions Through Delta-and Mu-Opioid Receptors," Annals New York Acad. Sci., 540, 691-693 (1988).
D. Kelleher et al., "Defective Suppression in the Autologous Mixed Lymphocyte Reaction in Patients with Crohn's Disease," Gut, 30, 839-844 (1989).
M. M. Kuntz et al., "Lymphocyte Transformation Induced by Autologous Cells IV. Human T-Lymphocyte Proliferation Induced by Autologous or Allogeneic Non-T Lymphcytes," J. Exp. Med., 143, 1042-1054 (1976).
A Laffon et al., "Differences in the Kinetics of the Autologous Mixed Lymphocyte Reaction Between the Various Connective Tissue Diseases," Rheumatol. Int., 3, 117-128 (1983).
D. Maric et al., "Enkaphalins and Immunity II, In Vivo Modulation of Cell-Mediated Immunity," Annals New York Acad Sci., 496, 126-136 (1987).
W. R. Martin, "Pharmacology of Opioids," Pharmacol. Rev., 35, 285-323 (1984).
P. S. Nagarkatti et al., "Characterization of an Endogenous Lyt 2+ T-Suppressor-Cell Population Regulating Autoreactive T Cells in Vitro and in Vivo," Cellular Immunol., 112, 64-77 (1988).
D. R. Oleson et al., "Regulation of Human Cytotoxicity by Enkephalins and Selective Opiate Agonists," Brain, Behavior, and Immunity,2, 171-186 (1988).
P. S. Portoghese et al., "Application of the Message-Address Concept in the Design of Highly Potent and Selective Non-Peptide .delta. Opioid Receptor Antagonists," J. Med. Chem., 31, 281-282 (Feb. 1988).
P. S. Portoghese et al., "Naltrindole, a Highly Selective and Potent Non-Peptide .delta. Opioid Receptor Anatagonist," Eur. J. Pharmacol., 146, 185-186 (1988).
P. A. Portoghese et al., "Naltrindole 5'-Isothiocyanate:A Nonequilibrium, Highly Selective .delta. Opioid Receptor Antagonist," J. Med. Chem., 33, 1547-1548 (1990).
J. W. Shaw et al., "Selective Antagonists at the Opiate Delta-Receptor,", Life Sci., 31, 1259-1262 (1982).
J. S. Smolen et al., "Responder Cells in the Human Autologous Mixed Lymphocyte Reaction," J. Clin. Invest., 68, 1601-1604 (Dec. 1981).
M. Sofouglu et al., "Differential Antagonism of Delta Opioid Agonists by Naltrindole and Its Benzofuran Analog (NBT) in Mice: Evidence for Delta Opioid Receptor Subtypes," J. Pharmacol. Exp. Therap., 257, 676-680 (1991).
N. Talal et al., "Impaired AMLR in Disease," Behring Inst. Mitt., 72, 169-176 (1983).
D. D. Taub et al., "Immunomodulatory Activity of .mu.-and "-Selective Opioid Agonists, Proc. Nat. Acad. Sci. USA, 88, 360-364 (Jan. 1991).
M. E. Weksler et al., "Lymphocyte Transformation Induced by Autologous Cells V. Generation of Immunologic Memory and Specificity During the Autologous Mixed Lymphocyte Reaction," J. Exp. Med., 146, 1833-1838 (1977).
J. Wybran et al., "Suggestive Evidence for Receptors for Morphine and Methionine-Enkephalin in Normal Blood T Lymphocytes," J. Immunol., 123, 1068-1070 (1979).
Linner Kristin M.
Portoghese Philip S.
Sharp Burt M.
Lambkin Deborah
Minneapolis Medical Research Foundation
Raymond Richard L.
Regents of the University of Minnesota
LandOfFree
Use of delta opioid receptor antagonists to treat immunoregulato does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of delta opioid receptor antagonists to treat immunoregulato, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of delta opioid receptor antagonists to treat immunoregulato will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1724109